Epax offers a wide range of high-quality omega-3 concentrates for the nutraceutical business-to-business segment.
Epax offers a wide range of high-quality omega-3 concentrates for the nutraceutical business-to-business segment, as well as pharmaceutical intermediates and active pharmaceutical ingredients. Recently, the company received the Frost & Sullivan Product Differentiation Excellence Award that recognizes Epax’s condition-specific range of concentrated EPA/DHA omega-3 ingredient products and the company’s success in carving out a niche in a crowded market. Epax is a world leader in marine-derived omega-3 fatty acid concentrates. The company says it has one of the best purity profiles in the industry. The Epax group is headquartered in Oslo, Norway, with cGMP manufacturing facilities in Ålesund, Norway, and Seal Sands, UK, and is a 50/50 joint venture between Aker BioMarine ASA and Lindsay Goldberg LLC.
Booth #25039
Recent animal study finds that Lysoveta may help reduce neonatal brain injury
July 17th 2024A recent animal study found that lysophosphatidylcholine (LPC)-bound omega-3 long-chain polyunsaturated fatty acids (LCPUFAs), marketed as Lysoveta by Aker BioMarine, protected against neonatal hypoxic-ischemic (HI) brain injury in mice.
Krill oil supplementation raises Omega-3 Index of Lupus patients in recent study
July 16th 2024The study was conducted at 20 research centers in the United States by Aker BioMarine and the Lupus Clinical Investigators Network with oversight by Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance.
Meta-analysis does not find increased risk of bleeding events from omega-3 PUFA consumption
July 8th 2024Researchers reviewed 11 studies and found that there was no difference in the incidence of bleeding events between patients receiving omega-3 PUFAs and those not receiving them. High dose EPA consumption was associated with an elevated but modest risk.
Recent review states that pentadecanoic acid may support cellular stability for better longevity
June 25th 2024According to the paper’s author, Stephanie Venn-Watson, DVM, MPH, deficiency in pentadecanoic acid of ≤0.2% total circulating fatty acids increases the risk of ferroptosis, which a type of cell death cause by the peroxidation of fragile fatty acids in cell membranes that combines with iron thus increasing reactive oxygen species, and disabling mitochondria.